19 Feb 2015 Posted in News Release By Press Office
Paul Catchpole, ABPI’s Director of Value and Access, said:
“This report is likely to be of some academic interest but should not be used as a basis for policy or decision making. It misses a fundamental point about how NHS investment decisions are made. Very few healthcare decisions are made using the QALY alone and in reality a wide range of other factors are used for decision making. A study commissioned by the ABPI* demonstrated that investment decisions made by local NHS organisations generally do not take into account the QALY. If a threshold of £13,000 were applied to decisions about all healthcare interventions then many vital services would cease to be considered viable including A&E, palliative care for dying patients and maternity services for new borns and their mothers.
“Life-enhancing and life-saving medicines cost money to develop and produce. However, as an industry, we are acutely aware of the cost pressures that the NHS operates under. That is why, via the pharmaceutical pricing agreement (PPRS), the industry is underwriting all medicines expenditure by the NHS over agreed levels, providing a unique opportunity to increase the availability and use of the best new and most innovative medicines, at minimal additional cost. In 2014 the pharmaceutical industry paid the Department of Health £229 million under this scheme. This year we are anticipating company payments to the Department of Health under this scheme to be approximately £800 million – and over the total five-year life of the scheme £4 billion.
“We would agree that the development of the Cancer Drugs Fund has been nothing more than a sticking plaster to fix a broken process and we firmly believe that NICE and NHSE need to change the way that medicines are evaluated and funded in order to create a system that is more responsive to provide timely access for all NHS patients to the new medicines that are being developed by the pharmaceutical industry. We are committed to working with all stakeholders to create this system and help the NHS deliver world-class healthcare where the right patient gets the right medicine at the right time.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811